RC-3095

• UNSPSC Description:

  RC-3095 is a bombesin/gastrin releasing peptide receptor (GRPR) antagonist[1]. RC-3095 exerts protective effects by reducing gastric oxidative injury in the arthritic mice[2].

• Target Antigen:

  Bombesin Receptor

• Type:

  Peptides

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/rc-3095.html

• Solubility:

  H2O

• Smiles:

  O=C([C@H]1CC(C(C=CC=C2)=C2N3)=C3CN1)N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@@H](C)C(N[C@@H](C(C)C)C(NCC(N[C@H](C(N[C@@H](CC(C)C)CN[C@H](C(N)=O)CC(C)C)=O)CC4=CN=CN4)=O)=O)=O)=O)CC5=CNC6=C5C=CC=C6)=O

• Molecular Weight:

  1106.32

• References & Citations:

  [1]Oliveira PG, et al. Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis. Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis. Arthritis Rheum. 2011 Oct;63(10):2956-65.|[2]Roesler R, et al. RC-3095, a bombesin/gastrin-releasing peptide receptor antagonist, impairs aversive but not recognition memory in rats. Eur J Pharmacol. 2004 Feb 13;486(1):35-41.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2

• CAS Number:

  138147-78-1